Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT air-trapping characterization to identify early benralizumab responders in eosinophilic asthma
2018-002292-18Phase 4Completed
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of benralizumab in eosinophilic asthma (EA), sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoint: Sensitivity and specificity of baseline E/I mean lung density for response prediction. Started Mar 2019; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2018-002292-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002292-18.